Adma Biologics (ADMA) closed at $18.26 in the latest trading session, marking a +1.44% move from the prior day. The stock's performance was ahead of the S&P 500's daily loss of 0.3%. Elsewhere, the Dow saw a downswing of 0.46%, while the tech-heavy Nasdaq depreciated by 0.38%. Shares of the infectious disease drug developer have depreciated by 1.15% over the course of the past month, underperforming the Medical sector's gain of 0.76%, and the S&P 500's gain of 3.64%.Market participants will be closely follo ...

Group 1 - Adma Biologics' stock closed at $18.34, reflecting a +2.98% change from the previous day's closing price, outperforming the S&P 500's daily gain of 0.61% [1] - The company has experienced a 14.62% decline in stock price over the past month, while the Medical sector saw a slight loss of 0.67% [1] Group 2 - The upcoming financial results for Adma Biologics are anticipated to show an EPS of $0.14, representing a 7.69% increase from the same quarter last year, with revenue expected to reach $121.1 million, a 12.98% rise year-over-year [2] - For the full year, analysts project earnings of $0.61 per share and revenue of $505.8 million, indicating increases of +24.49% and +18.61% respectively compared to the previous year [3] Group 3 - Recent changes to analyst estimates for Adma Biologics are seen as reflective of short-term business dynamics, with positive revisions indicating a favorable business outlook [3] - The Zacks Rank system, which evaluates estimate changes, currently ranks Adma Biologics at 4 (Sell), with the consensus EPS estimate having decreased by 8.27% in the past month [5] Group 4 - Adma Biologics is trading at a Forward P/E ratio of 29.2, which is a premium compared to the industry average Forward P/E of 19.46 [6] - The Medical - Biomedical and Genetics industry, to which Adma Biologics belongs, holds a Zacks Industry Rank of 75, placing it in the top 31% of over 250 industries [6]

Company Performance - Adma Biologics closed at $18.16, reflecting a -1.3% change from the previous day, underperforming the S&P 500's gain of 0.52% [1] - The stock has decreased by 6.93% over the past month, while the Medical sector gained 3.5% and the S&P 500 increased by 5.95% [1] Upcoming Earnings - Adma Biologics is projected to report earnings of $0.14 per share, indicating a year-over-year growth of 7.69% [2] - The Zacks Consensus Estimate for revenue is $121.1 million, representing a 12.98% increase from the previous year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are estimated at $0.61 per share and revenue at $505.8 million, showing increases of +24.49% and +18.61% respectively from the prior year [3] - Recent changes in analyst estimates reflect shifting business dynamics, with positive adjustments indicating optimism regarding business and profitability [3] Valuation Metrics - Adma Biologics has a Forward P/E ratio of 30.16, compared to the industry average of 19.05, suggesting it is trading at a premium [6] - The Medical - Biomedical and Genetics industry ranks in the top 34% of all industries, with a current Zacks Industry Rank of 83 [6] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a strong track record, with 1 rated stocks delivering an average annual return of +25% since 1988 [5] - Adma Biologics currently holds a Zacks Rank of 3 (Hold), with a recent 8.27% decrease in the Consensus EPS estimate over the last 30 days [5]

Company Overview - ADMA Biologics specializes in plasma-derived biologics aimed at treating immune deficiencies and preventing certain infectious diseases [1] - The company's flagship product, Asceniv, is an intravenous immune globulin that contains naturally occurring polyclonal antibodies, indicated for treating primary immunodeficiency disease in adults and adolescents [1] Financial Performance - In the first quarter, ADMA reported revenues of $114.8 million, primarily driven by record sales of Asceniv [2][8] - The recent FDA approval of a yield enhancement production process is expected to increase finished immunoglobulin output by 20%, supporting revenue growth and margin expansion [2] - ADMA projects revenues exceeding $500 million in 2025 and $625 million in 2026 [2] Market Dynamics - An increase in new patient starts and deeper market penetration is anticipated to significantly boost Asceniv's sales [3] - ADMA's intellectual property portfolio, which includes proprietary plasma screening assays and unique plasma pooling methods, provides brand protection until at least 2035, with potential extensions beyond that [3] Competitive Landscape - ADMA competes with major players in the plasma therapy market, including Grifols and Takeda [4] - Grifols is a leading global producer of plasma derivatives, with a strong presence in various segments, including immunoglobulins and albumin [5] - Takeda offers a broad immunoglobulin portfolio and is developing next-generation IG products to diversify its offerings [6] Valuation and Estimates - ADMA's shares have increased by 7.3% year-to-date, contrasting with a 2.6% decline in the industry [7] - The company currently trades at a price/sales ratio of 7.68x, significantly higher than its historical mean of 3.33x and the industry's average of 1.64x, indicating a potentially expensive valuation [10] - Recent earnings per share estimates for 2025 and 2026 have been revised downward, reflecting increased competition in the plasma therapy market [12]

Core Insights - ADMA Biologics and Takeda are prominent players in the plasma-derived immunoglobulin sector, with ADMA focusing on treatments for immune deficiencies and Takeda having a diversified portfolio across various therapeutic areas [1][8]. ADMA Biologics - ADMA markets three FDA-approved plasma-derived products: Bivigam, Asceniv, and Nabi-HB, targeting immune deficiencies and infectious diseases [3][10]. - Asceniv, ADMA's lead product, is a plasma-derived IVIG that contains polyclonal antibodies, crucial for neutralizing microbes [4][5]. - Record demand for Asceniv was noted in Q1, with expectations for revenue growth through 2025 and plans for a pediatric label expansion filing by mid-2025 [6][10]. - ADMA anticipates proof-of-concept data for its pipeline program SG-001 by the end of 2025, with potential annual revenues of $300-500 million [7]. Takeda - Takeda's plasma-derived therapies (PDT) business unit has shown 9% growth in 2024, supported by a broad immunoglobulin portfolio including Hyqvia, Cuvitru, and Gammagard [8][10]. - Hyqvia is notable for being the only subcutaneous IG treatment for primary immunodeficiencies, requiring fewer infusions [11]. - Takeda is actively developing next-generation immunoglobulin products and has partnered with other companies to enhance its pipeline [13][14]. Financial Estimates and Performance - The Zacks Consensus Estimate for ADMA's 2025 sales indicates an 18.61% year-over-year increase, while EPS estimates have shown mixed movements [15]. - In contrast, Takeda's 2025 sales estimates suggest a 2.80% decrease, with EPS showing a 6.21% improvement [16]. - Year-to-date, Takeda's stock has outperformed ADMA, with gains of 13.91% compared to ADMA's 4.1% [18]. - Valuation metrics indicate ADMA is trading at 21.79X forward earnings, significantly higher than Takeda's 9.03X [18]. Investment Considerations - Takeda is recognized for its stability and broad portfolio, making it a safer investment choice, while ADMA's growth potential is tied to the expansion of Asceniv [21][22]. - Despite Takeda's current ranking as a "Sell," ADMA's revenue potential from Asceniv positions it as a more attractive investment opportunity at present [22][23].

Adma Biologics (ADMA) ended the recent trading session at $17.74, demonstrating a -2.15% change from the preceding day's closing price. This change lagged the S&P 500's daily loss of 0.22%. At the same time, the Dow added 0.08%, and the tech-heavy Nasdaq lost 0.51%. The infectious disease drug developer's stock has dropped by 10.07% in the past month, falling short of the Medical sector's loss of 0% and the S&P 500's gain of 0.45%.Analysts and investors alike will be keeping a close eye on the performance o ...

Key Takeaways ADMA saw record demand for Asceniv and plans a 2025 filing to expand into pediatric use. Label expansion and new patient starts are expected to drive growth in Asceniv sales. ADMA trades at 8.75X forward sales, above its historical average and industry valuation levels.ADMA Biologics (ADMA) markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.ADMA’s lead product, Asceniv, is a plasma-derived Intravenous Immune Globulin th ...

Core Viewpoint - The article updates the previous coverage of ADMA Biologics, indicating a shift from a "Strong Buy" rating to a "Hold" due to the presence of better investment opportunities in the market [1]. Company Analysis - ADMA Biologics holds a strong position in the biologics market, characterized by a unique profile that initially attracted significant investment interest [1]. - The investment firm Libra Capital was established in 2022, focusing on deep research into companies before making investment decisions [1]. Investment Strategy - A "Hold" rating suggests that investors should neither buy nor short the stock, as there are perceived to be more attractive opportunities available [1].

ADMA Biologics (ADMA) has been a consistent market outperformer in recent times. Shares have gained 17.2% in the past three months against the industry’s decline of 10.6%. The stock has also outperformed the sector and the S&P 500 in this timeframe.ADMA Outperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.Though the first-quarter results (reported ...

Core Viewpoint - ADMA Biologics and Grifols are prominent players in the plasma-derived therapies market, each with unique strengths and growth prospects, making stock selection challenging [1][2]. Company Overview ADMA Biologics - ADMA specializes in plasma-derived biologics for treating immune deficiencies and preventing infectious diseases, with three FDA-approved products: Bivigam, Asceniv, and Nabi-HB [3][6]. - Asceniv, the lead product, is a plasma-derived IVIG that contains polyclonal antibodies to neutralize microbes [4][5]. - The company anticipates significant revenue growth from Asceniv, driven by record demand and plans for a new R&D program, SG-001, which could generate $300-500 million in annual revenues [6]. Grifols - Grifols is a global leader in plasma-derived medicines, developing a wide range of biological therapies targeting various immunological conditions [7][8]. - The company reported sales of €7.2 billion in 2024, reflecting a 10.3% increase, and is recognized as the largest producer of A1PI [9][10]. - Grifols has a diverse portfolio and is positioned for consistent growth due to strong demand and operational execution [11]. Financial Estimates ADMA Biologics - The Zacks Consensus Estimate for ADMA's 2025 sales indicates an 18.61% year-over-year increase, with EPS expected to improve by 36.73% [12]. - Recent estimate revisions show a decline in EPS estimates for 2025 but an increase for 2026 [13]. Grifols - The Zacks Consensus Estimate for Grifols' 2025 sales suggests a 3.78% increase, with EPS expected to rise by 296% [12]. - EPS estimates for both 2025 and 2026 have seen upward revisions in the past 60 days [15]. Price Performance and Valuation - Year-to-date, ADMA shares have increased by 15.9%, outperforming Grifols' 10.6% rise, while the industry has declined by 4.1% [16]. - In terms of valuation, ADMA trades at 25.48X forward earnings, significantly higher than Grifols' 7.19X [16]. Investment Recommendation - ADMA shows steady growth driven by Asceniv demand, while Grifols, with a broader portfolio and better valuation, is considered a more favorable investment choice at present [20][21][22].